Evidence map›Paper›PMID 31040575›Full record

ArticleVeterinary world2019

Antiretroviral activity of

Andy Noorsaman Sommeng, R Muhammad Yusuf Arya, Mikael Januardi Ginting, Diah Kartika Pratami, Heri Hermansyah, Muhamad Sahlan, Anondho Wijanarko

Open access · goldAbstract read
In one paragraph

Article in Veterinary world, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Antiviral Effects of Animal Toxins: Is There a Way to Drugs?International journal of molecular sciences · 2022
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Andy Noorsaman SommengDepartment of Chemical Engineering, Faculty of Engineering, Universitas Indonesia, Indonesia.
R Muhammad Yusuf AryaDepartment of Chemical Engineering, Faculty of Engineering, Universitas Indonesia, Indonesia.
Mikael Januardi GintingMarine Science Postgraduate Program, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Indonesia.
Diah Kartika PratamiLaboratory of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Pancasila University, Indonesia.
Heri HermansyahDepartment of Chemical Engineering, Faculty of Engineering, Universitas Indonesia, Indonesia.
Muhamad SahlanDepartment of Chemical Engineering, Faculty of Engineering, Universitas Indonesia, Indonesia.
Anondho WijanarkoDepartment of Chemical Engineering, Faculty of Engineering, Universitas Indonesia, Indonesia.
University of Indonesia · IDPancasila University · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThis study aimed to investigate the antiviral activity of MATERIALS AND

methodsFresh venomous fin parts of wild PV specimens were collected from Java Sea waters. Then, it washed using phosphate buffer pH 7.0 and immersed in phosphate buffer pH 7.0 0.01 m containing CaCl

resultsThe protein's activity, concentration, and purity analysis revealed that the PV-PLA2 purified using ammonium sulfate fractionation has the highest activity (1.81 times higher than the CV at 80% fractionation) and has higher purity than the sample from ET fractionation. The testing of the sample purified using ammonium sulfate fractionation at 80% saturation level shown that it has a 97.78% inhibition level toward SRV2-A549 culture at 4 ppm. However, in comparison to lamivudine which has 99.55% inhibition level at 100 ppm, it needs much lower concentration to achieve the same result.

conclusionThe significant inhibition of SRV2-A549 culture shown that the PV-PLA2 extracted from PV venom has the potential to become anti-HIV substances. It would be worthwhile to further evaluate the antiretroviral activity of PV-PLA2 in the

Indexed as

antiretroviruslamivudinephospholipase A2Pterois volitanssimian retrovirus serotype 2

Identifiers

PMID31040575
PMCPMC6460858
OpenAlexW2917595572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.